Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis
eRapa-FAP
Expanded Access Program for 0.5 mg eRapa in Familial Adenomatous Polyposis
1 other identifier
expanded_access
N/A
0 countries
N/A
Brief Summary
This expanded access program provides 0.5 mg eRapa (encapsulated rapamycin) to patients with familial adenomatous polyposis (FAP) who have no satisfactory alternative treatment options and are not eligible to participate in a clinical trial. The objective is to provide access to eRapa based on the treating physician's assessment that the potential benefits outweigh the potential risks, with appropriate clinical monitoring for safety and tolerability.
Trial Health
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 30, 2026
CompletedFirst Posted
Study publicly available on registry
July 8, 2026
CompletedJuly 8, 2026
June 1, 2026
June 30, 2026
June 30, 2026
Conditions
Keywords
Interventions
eRapa is a proprietary oral encapsulated formulation of rapamycin (sirolimus) provided as 0.5 mg capsules. This expanded access program uses the 0.5 mg formulation specifically developed for long-term administration.
Eligibility Criteria
You may qualify if:
- Patient is post pubertal and reached full adult height
- Patient has FAP confirmed by APC genotype mutation tesing or a history of FAP in one of the parents. Genetic mosaics or Attenuated (as well as classical) FAP may participate
- Patient has significant colorectal and/or duodenal FAP disease burden.
You may not qualify if:
- Patient has existing carcinoma or high-grade dysplasia in the GI tract and/or requires imminent definitive surgical intervention (either partial or complete colectomy or duodenectomy).
- Patient with an acquired or congenital immunodeficiency, active and clinically significant tuberculosis, bacterial, fungal, or viral infections, including HIV.
- Patient has clinically significant elevations of hepatic enzymes or bilirubin, or other evidence of active hepatitis.
- Patient has clinically significant impairment of renal function.
- Patient has a history or evidence of clinically significant hyperlipoproteinemia or hypertriglyceridemia.
- Patient has active or recurrent bouts of pancreatitis, or clinically significant elevations of lipase or amylase.
- Patient is taking medications that are considered strong inducers or inhibitors of cytochrome P450 (CYP) 3A4/5 or strong inducers or inhibitors of P-glycoprotein 1 (P-gp1) that cannot be discontinued at least 1 week prior to first dose of treatment intervention and for the duration of the treatment.
- Patients with known hypersensitivity to rapamycin (sirolimus) or any of the excipients in eRapa.
- Sexually active patients who are unwilling to use a highly effective contraceptive method and to refrain from donating gametes (sperm or oocytes) throughout the time they are receiving eRAPA and for 12 weeks beyond that time, and to refrain from breast-feeding their children while on treatment.
- Patients who are pregnant or who are trying to become pregnant while taking eRapa.
- Patients unwilling or unable to undergo continued endoscopic surveillance in accordance with standards of care while taking eRapa.
- Patient has Mutations in the MUTYH gene.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 30, 2026
First Posted
July 8, 2026
Last Updated
July 8, 2026
Record last verified: 2026-06